Indivior (NASDAQ:INDV) Shares Gap Down – Time to Sell?

Indivior PLC (NASDAQ:INDV)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $10.91, but opened at $8.98. Indivior shares last traded at $9.50, with a volume of 538,734 shares changing hands.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Rodman & Renshaw assumed coverage on shares of Indivior in a report on Tuesday, January 28th. They set a “buy” rating and a $16.00 price target on the stock. Piper Sandler reissued an “overweight” rating and issued a $16.00 target price (up previously from $15.00) on shares of Indivior in a report on Friday, October 25th. Finally, RODMAN&RENSHAW raised shares of Indivior to a “strong-buy” rating in a report on Tuesday, January 28th.

Indivior Stock Down 5.8 %

The company has a market cap of $1.17 billion, a PE ratio of -24.19 and a beta of 0.73. The stock’s 50 day moving average is $11.51 and its 200-day moving average is $10.87.

Indivior (NASDAQ:INDV) last released its quarterly earnings results on Thursday, February 20th. The company reported $0.32 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.32. The company had revenue of $298.00 million for the quarter, compared to the consensus estimate of $262.35 million. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. On average, analysts anticipate that Indivior PLC will post 1.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Rathbones Group PLC increased its position in Indivior by 11.6% during the fourth quarter. Rathbones Group PLC now owns 14,284 shares of the company’s stock valued at $183,000 after acquiring an additional 1,483 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Indivior by 4.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 41,327 shares of the company’s stock valued at $408,000 after acquiring an additional 1,888 shares during the last quarter. Two Sigma Investments LP increased its position in Indivior by 2.1% during the fourth quarter. Two Sigma Investments LP now owns 110,880 shares of the company’s stock valued at $1,378,000 after acquiring an additional 2,237 shares during the last quarter. Stifel Financial Corp increased its position in Indivior by 24.0% during the fourth quarter. Stifel Financial Corp now owns 12,675 shares of the company’s stock valued at $158,000 after acquiring an additional 2,450 shares during the last quarter. Finally, PDT Partners LLC increased its position in Indivior by 4.7% during the fourth quarter. PDT Partners LLC now owns 57,520 shares of the company’s stock valued at $715,000 after acquiring an additional 2,596 shares during the last quarter. Institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.